Event next week: Supporting the next generation of lifesaving medicines

Andrew Powaleny
Andrew Powaleny July 12, 2018


Share This

The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more than 140,000 biopharmaceutical researchers willing to confront seemingly impossible goals. Yet, for many patients with complex, rare or life-threatening diseases, even a single treatment option remains elusive.

Tuesday, July 17, in partnership with The Atlantic, PhRMA will bring together a diverse group of thought leaders to examine the policies that have fostered the new era of medicine and discuss how we continue to support the next generation of lifesaving therapies to benefit patients. 

The event, The State of Care: Innovation and Access, will include an interview with Eli Lilly and Company CEO David Ricks on the industry’s role in advancing patient care. Also included will be a discussion with organ donor advocate Roxanne Watson, featured as part of PhRMA’s GOBOLDLY campaign, on how she benefited from innovative anti-rejection medicines after a heart transplant. Roxanne will be joined by Sharon Terry, president and CEO of the Genetic Alliance in a conversation that will be moderated by Deloitte Consulting’s managing director, Margaret Anderson.

The event will also feature a keynote interview with the Director of the U.S. Patent and Trademark Office Andrei Iancu and a panel of experts discussing the policy environment needed to support continued investment in biopharmaceutical research.

While we have made significant strides, we cannot take the rapid pace of innovation for granted. From strong intellectual property protections to regulations that support innovative payment models, a wide range of policies play a critical role in ensuring that every patient has an opportunity to triumph over their disease.

Join us online on Tuesday, July 17, from 8:15 a.m. to 10:00 a.m. EST to hear from this distinguished group of experts.

Topics: Access, Intellectual Property, GoBoldly